Evaluating the structural and immune mechanism of Interleukin-6 for the investigation of goat milk peptides as potential treatments for COVID-19.

Sundaresan Bhavaniramya, Ashokkumar Sibiya, Abdulaziz S Alothaim, Ayoub Al Othaim, Vanajothi Ramar, Alaguraj Veluchamy, Palanisamy Manikandan, Baskaralingam Vaseeharan
Author Information
  1. Sundaresan Bhavaniramya: Biomaterials and Biotechnology in Animal Health Lab, Department of Animal Health and Management, Alagappa University, Karaikudi, Tamil Nadu, India.
  2. Ashokkumar Sibiya: Biomaterials and Biotechnology in Animal Health Lab, Department of Animal Health and Management, Alagappa University, Karaikudi, Tamil Nadu, India.
  3. Abdulaziz S Alothaim: Department of Biology, College of Science in Zulfi, Majmaah University, Majmaah 11952, Saudi Arabia.
  4. Ayoub Al Othaim: Department of Medical Laboratories, College of Applied Medical Sciences, Majmaah University, Al-Majmaah 11952, Saudi Arabia.
  5. Vanajothi Ramar: Department of Biomedical Science, Bharathidasan University, Tiruchirappalli 620024, India.
  6. Alaguraj Veluchamy: Biological and Environmental Science and Engineering Division, King Abdullah University of Science and Technology, Thuwal 23955, Saudi Arabia.
  7. Palanisamy Manikandan: Department of Medical Laboratories, College of Applied Medical Sciences, Majmaah University, Al-Majmaah 11952, Saudi Arabia.
  8. Baskaralingam Vaseeharan: Biomaterials and Biotechnology in Animal Health Lab, Department of Animal Health and Management, Alagappa University, Karaikudi, Tamil Nadu, India.

Abstract

The function of Immune control, haematopoiesis, and inflammation all depend on the cytokine Interleukin 6 (IL-6), and higher expression of IL-6 is seen in COVID-19 and other diseases. The immune protein IL-6 activation is dependent on binding interactions with IL-6Rα, mIL-6R, and sIL-6R for its cellular function. Termination of these reaction could benefit for controlling the over-expression in COVID-19 patients and that may arise as inhibitors for controlling COVID-19. Traditionally, the goat milk has been prescribed as medicine in ayurvedic practice and through this work, we have explored the benefits of peptides from goat milk as IL-6 inhibitors, and it have the potential of inhibiting the over expression of IL-6 and control the COVID-19 disease. Computational experiments have shown that goat peptides had strong interactions with IL-6, with higher scoring profiles and energy efficiency ranging from -6.00 kcal/mol to -9.00 kcal/mol in docking score and -39.00 kcal/mol in binding energy. Especially the YLGYLEQLLR, VLVLDTDYK and AMKPWIQPK peptides from goat milk holds better scoring and shows strong interactions were identified as the most potential IL-6 inhibitor candidates in this study. Peptides from Goat proteins, which are capable of binding to the IL-6 receptor with strong binding conformations, have no negative effects on other immune system proteins.

Keywords

References

  1. J Comput Chem. 2005 Dec;26(16):1701-18 [PMID: 16211538]
  2. Proteins. 2021 Feb;89(2):163-173 [PMID: 32881084]
  3. J Chem Inf Model. 2013 Jul 22;53(7):1689-99 [PMID: 23800267]
  4. Aging (Albany NY). 2021 Nov 3;13(21):23913-23935 [PMID: 34731090]
  5. Sci Rep. 2021 Mar 10;11(1):5619 [PMID: 33692444]
  6. BMC Bioinformatics. 2013;14 Suppl 6:S4 [PMID: 23735058]
  7. ACS Infect Dis. 2021 Jun 11;7(6):1389-1408 [PMID: 33346633]
  8. Int J Mol Sci. 2021 Jul 27;22(15): [PMID: 34360756]
  9. Bioorg Med Chem Lett. 2020 Dec 15;30(24):127613 [PMID: 33075488]
  10. EMBO J. 1997 Mar 3;16(5):989-97 [PMID: 9118960]
  11. Mol Cells. 2021 Jun 30;44(6):408-421 [PMID: 34059561]
  12. J Proteomics. 2020 Sep 15;227:103916 [PMID: 32711164]
  13. Food Chem Toxicol. 2018 Feb;112:495-506 [PMID: 28843597]
  14. Curr Mol Pharmacol. 2022;15(2):418-433 [PMID: 34488601]
  15. Virus Res. 2020 Oct 15;288:198114 [PMID: 32800805]
  16. Mol Divers. 2022 Jun;26(3):1893-1913 [PMID: 34686947]
  17. J Chem Inf Model. 2011 Oct 24;51(10):2515-27 [PMID: 21877713]
  18. J Comput Aided Mol Des. 2013 Mar;27(3):221-34 [PMID: 23579614]
  19. Bioinformatics. 2019 Sep 1;35(17):3020-3027 [PMID: 30657872]
  20. Curr Mol Pharmacol. 2022;15(2):393-417 [PMID: 34382513]
  21. Eur J Pharmacol. 2021 Jan 15;891:173781 [PMID: 33271151]
  22. J Chem Inf Model. 2015 Aug 24;55(8):1686-97 [PMID: 26270943]
  23. Cell Commun Signal. 2021 Jan 13;19(1):7 [PMID: 33441142]
  24. Nat Rev Rheumatol. 2020 Jun;16(6):335-345 [PMID: 32327746]
  25. Appl Biochem Biotechnol. 2014 Feb;172(4):1790-806 [PMID: 24264995]
  26. J Biomol Struct Dyn. 2021 Jan;39(1):272-284 [PMID: 31920173]
  27. J Autoimmun. 2020 Jul;111:102452 [PMID: 32291137]
  28. Headache. 2020 Jul;60(7):1422-1426 [PMID: 32413158]
  29. Signal Transduct Target Ther. 2020 Oct 13;5(1):237 [PMID: 33051445]
  30. Rev Med Virol. 2020 Nov;30(6):1-9 [PMID: 32845568]
  31. Nucleic Acids Res. 2018 Jul 2;46(W1):W443-W450 [PMID: 29746661]
  32. N Engl J Med. 2021 Jan 7;384(1):20-30 [PMID: 33332779]
  33. Mol Biosyst. 2015 Jan;11(1):178-89 [PMID: 25335799]
  34. Nucleic Acids Res. 2005 Jul 1;33(Web Server issue):W363-7 [PMID: 15980490]
  35. Nature. 2020 Mar;579(7798):265-269 [PMID: 32015508]

Word Cloud

Created with Highcharts 10.0.0IL-6COVID-19goatbindingmilkpeptidesInterleukin6immuneinteractionspotentialstrong00 kcal/molGoatfunctioncontrolhigherexpressioncontrollinginhibitorsscoringenergydockingproteinsreceptorImmunehaematopoiesisinflammationdependcytokineseendiseasesproteinactivationdependentIL-6RαmIL-6RsIL-6RcellularTerminationreactionbenefitover-expressionpatientsmayariseTraditionallyprescribedmedicineayurvedicpracticeworkexploredbenefitsinhibitingdiseaseComputationalexperimentsshownprofilesefficiencyranging-6-9score-39EspeciallyYLGYLEQLLRVLVLDTDYKAMKPWIQPKholdsbettershowsidentifiedinhibitorcandidatesstudyPeptidescapableconformationsnegativeeffectssystemEvaluatingstructuralmechanismInterleukin-6investigationtreatmentsMilkMDsimulationPeptide

Similar Articles

Cited By